. As of December31, 2025, we had an accumulated deficit of $561.7 million. We currently rely and expect to continue to rely on third parties for the manufacture of our product candidates for preclinical and clinical testing and for commercial supply of PYRUKYND and AQVESME and any product candidate for which we may obtain marketing approval. Any performance failure on the part of our existing or future third-party manufacturers could delay clinical development, marketing approval or our commerci...
Q2 FY2026 — expected 2026-08-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-12 | 2025-12-31 | 0001439222-26-000025 | EDGAR | 87K words |
| 2025-02-13 | 2024-12-31 | 0001439222-25-000009 | EDGAR | — |
| 2024-02-15 | 2023-12-31 | 0001439222-24-000035 | EDGAR | — |
| 2023-02-23 | 2022-12-31 | 0001439222-23-000039 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0001439222-22-000024 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001439222-21-000029 | EDGAR | — |
| 2020-02-19 | 2019-12-31 | 0001439222-20-000014 | EDGAR | — |
| 2019-02-14 | 2018-12-31 | 0001439222-19-000004 | EDGAR | — |
| 2018-02-14 | 2017-12-31 | 0001439222-18-000004 | EDGAR | — |
| 2017-02-16 | 2016-12-31 | 0001193125-17-046795 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-10-30 | 2025-09-30 | 0001439222-25-000116 | EDGAR | 44K words |
| 2025-07-31 | 2025-06-30 | 0001439222-25-000089 | EDGAR | — |
| 2025-05-01 | 2025-03-31 | 0001439222-25-000036 | EDGAR | — |
| 2024-10-31 | 2024-09-30 | 0001439222-24-000138 | EDGAR | — |
| 2024-08-01 | 2024-06-30 | 0001439222-24-000121 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0001439222-24-000069 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0001439222-23-000140 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001439222-23-000119 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001439222-23-000065 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001439222-22-000099 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001439222-22-000070 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001439222-22-000040 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-12 | 0001439222-26-000023 | EDGAR | 2K words |
| 2026-01-12 | 0001439222-26-000018 | EDGAR | — |
| 2025-10-30 | 0001439222-25-000114 | EDGAR | — |
| 2025-08-04 | 0001439222-25-000090 | EDGAR | — |
| 2025-07-31 | 0001439222-25-000087 | EDGAR | — |
| 2025-07-08 | 0001439222-25-000076 | EDGAR | — |
| 2025-06-18 | 0001193125-25-142745 | EDGAR | — |
| 2025-05-01 | 0001439222-25-000034 | EDGAR | — |
| 2025-02-13 | 0001439222-25-000007 | EDGAR | — |
| 2025-02-13 | 0001193125-25-025524 | EDGAR | — |
218 total filings indexed. 186 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001439222 |
| Ticker | AGIO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.agios.com |
| Listed | 2013-07-24 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report